Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies
https://doi.org/10.18008/1816-5095-2019-2-151-158
Abstract
Polypoidal choroidal vasculopathy (PCV) is a rare subtype of neovascular age-related macular degeneration (AMD), its specific features are abnormal branching vascular network with aneurysmal dilatations (polyps), it can be diagnosed in indocyanine green angiography. PCV differs from typical AMD by some ophthalmoscopic manifestations, multimodal imaging data as angiography, OCT with the ability to visualize the choroid, OCT-angiography and expression of VEGF. Despite the different response to antiangiogenic therapy, the presence of pathological neovascularization requires anti-VEGF treatment for both AMD types. In this review, we summarize the latest literature data on the treatment of polyphoidal choroidal vasculopathy: anti-VEGF monotherapy, photodynamic monotherapy, and their combinations. Special attention is paid to the results of multicenter randomized clinical trials with a large number of patients evaluating efficacy of Ranibizumab and Aflibercept (EVEREST 2 and PLANET). The short-term and long-term results of treatment are presented, taking into account the dosing regimens, the number of required injections and the requirement for a combination of anti-VEGF monotherapy with photodynamic therapy. The results of randomized clinical trial are providing high level evidence to guide clinical specialists in choosing the most appropriate therapy for PCV.
About the Authors
E. K. Pedanova
S. Fyodorov Eye Microsurgery Federal State Institution
Beskudnikovskiy blvd, 59A, Moscow, 127486
Russian Federation
Russian Federation
PhD,
researcher Beskudnikovskiy blvd, 59A, Moscow, 127486
A. V. Doga
S. Fyodorov Eye Microsurgery Federal State Institution
Russian Federation
Russian Federation
MD, professor, deputy CEO for Scientific and Clinical work,
Beskudnikovskiy blvd, 59A, Moscow, 127486
References
1. Spaide R.F., Yannuzzi L.A., Slakter J.S., Sorenson J., Orlach D.A. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15(2):100–110.
2. Honda S., Matsumiya W., Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition. Ophthalmologica. 2014;231(2):59–74. DOI: 10.1159/000355488
3. Hatz K., Prünte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response Br J Ophthalmol. 2014 Feb;98(2):188–194. DOI: 10.1136/bjophthalmol-2013-303444 4. Yannuzzi L., Sorenson J., Spaide R.F., Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1–8.
4. Stern R.M., Zakov Z.N., Zegarra H., Gutman F.A. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol. 1985 Oct 15;100(4):560–569.
5. Kleiner R.C., Brucker A.J., Johnston R.L. The posterior uveal bleeding syndrome. Retina. 1990;10(1):9–17.
6. Yannuzzi L.A., Ciardella A., Spaide R.F., Rabb M., Freund K.B., Orlock D.A. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997 Apr;115(4):478–85.
7. Yannuzzi L.A., Wong D.W., Sforzolini B.S., Goldbaum M., Tang K.C., Spaide R.F., Freund K.B., Slakter J.S., Guyer D.R., Sorenson J.A., Fisher Y., Maberley D., Orlock D.A. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999 Nov;117(11):1503–1510.
8. Lim T.H., Laude A., Tan C.S. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye (Lond). 2010 Mar;24(3):483–490. DOI: 10.1038/eye.2009.323
9. Khan S., Engelbert M., Imamura Y., Freund K.B. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings. Retina. 2012 Jun;32(6):1057–1068. DOI: 10.1097/IAE.0b013e31823beb14
10. Rosa R.H. Jr, Davis J.L., Eifrig C.W. Clinicopathologic Correlation of Idiopathic Polypoidal Choroidal Vasculopathy. Arch Ophthalmol. 2002 Apr;120(4):502–508.
11. Nakashizuka H., Mitsumata M., Okisaka S., Shimada H., Kawamura A., Mori R., Yuzawa M. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4729–4737. DOI: 10.1167/iovs.08-2134
12. Kawamura A., Yuzawa M., Mori R., Haruyama M., Tanaka K. Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol. 2013 Sep;91(6):e474–e481. DOI: 10.1111/aos.12110
13. Dansingani K.K., Gal-Or O., Sadda S.R., Yannuzzi L.A., Freund K.B. Understanding aneurysmal type 1 neovascularisation (polypoidal choroidal vasculopathy): a lesson in the taxonomy of “expanded spectra”. Clin Exp Ophthalmol. 2018 Mar;46(2):189– 200. DOI: 10.1111/ceo.13114
14. Imamura Y., Engelbert M., Iida T., Freund K.B., Yannuzzi L.A. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010 Nov-Dec;55(6):501–515. DOI: 10.1016/j.survophthal.2010.03.004
15. Chung S.E., Kang S.W., Lee J.H., Kim Y.T. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology. 2011 May;118(5):840–845. DOI: 10.1016/j.ophtha.2010.09.012
16. Laude A., Cackett P.D., Vithana E.N., Yeo I.Y., Wong D., Koh A.H., Wong T.Y., Aung T. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010 Jan;29(1):19-29. doi: 10.1016/j.preteyeres.2009.10.001.
17. Tong J.P., Chan W.M., Liu D.T., Lai T.Y., Choy K.W., Pang C.P., Lam D.S. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141:456‒462.
18. Matsuoka M., Ogata N., Otsuji T., Nishimura T., Takahashi K., Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004 Jun;88(6):809–815.
19. Lee M.Y., Lee W.K., Baek J., Kwon O.W., Lee J.H. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor. Am J Ophthalmol. 2013 Aug;156(2):343–348. DOI: 10.1016/j.ajo.2013.04.001
20. Cheung C.M.G., Lai T.Y.Y., Ruamviboonsuk P., Chen S.J., Chen Y., Freund K.B., Gomi F., Koh A.H., Lee W.K., Wong T.Y. Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018 May;125(5):708–724. DOI: 10.1016/j.ophtha.2017.11.019
21. Mayorova A.M., Doga A.V., Pedanova E.K., Volodin P.L. Autofluorescence of the fundus in the complex diagnosis of polypoid choroidal vasculopathy. Modern technologies in ophthalmology = Sovremennye tekhnologii v oftal’mologii. 2017;4:141–143 (In Russ.).
22. Panova I.E., Shaimov T.B., Shaimova V.A. Non-Invasive Diagnosis of Polypoidal Choroidal Vasculopathy as a Variant of the Course of Age-Related Macular Degeneration. Ophthalmology in Russia = Ophthal’mologiya. 2018;15(2S):273–280 (In Russ.). DOI: 10.18008/1816-5095-2018-2S-273-280
23. Tan C.S., Ngo W.K., Chen J.P., Tan N.W., Lim T.H.; EVEREST Study Group. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy Br J Ophthalmol. 2015 May;99(5):624–628. DOI: 10.1136/bjophthalmol-2014-305674
24. Shaimov T.B., Panova I.E., Shaimova V.A. Indocyanine green angiography in the algorithm of diagnostics of polypoidal chrioidal vasculopathy in age-related macular degeneration. Practical medicine = Prakticheskaya meditsina. 2017;2(9,110):253–258 (In Russ.).
25. Gomi F., Ohji M., Sayanagi K., Sawa M., Sakaguchi H., Oshima Y., Ikuno Y., Tano Y. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115(1):141e146 DOI: 10.1016/j.ophtha.2007.02.031
26. Akaza E., Yuzawa M., Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011 Jan;55(1):39–44. DOI: 10.1007/s10384-010-0886-x
27. Wong C.W., Cheung C.M., Mathur R., Li X., Chan C.M., Yeo I., Wong E., Lee S.Y., Wong D., Wong T.Y. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina. 2015 Aug;35(8):1577–1593. DOI: 10.1097/IAE.0000000000000499
28. Tsuchiya D., Yamamoto T., Kawasaki R., Yamashita H. Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina. 2009 JulAug;29(7):960–955. DOI: 10.1097/IAE.0b013e3181a3b7c5
29. Gomi F., Sawa M., Sakaguchi H., Tsujikawa M., Oshima Y., Kamei M., Tano Y. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008 Jan;92(1):70–73.
30. Lai T.Y., Lee G.K., Luk F.O., Lam D.S. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina. 2011 Sep;31(8):1581–1588. DOI: 10.1097/IAE.0b013e31820d3f3f
31. Ogino K., Tsujikawa A., Yamashiro K., Ooto S., Oishi A., Nakata I., Miyake M., Yoshimura N. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2013 May 1;54(5):3771–3779. DOI: 10.1167/iovs.12-11494
32. Kang H.M., Koh H.J. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013 Oct;156(4):652–660. DOI: 10.1016/j.ajo.2013.05.038
33. Kokame G.T., Yeung L., Teramoto K., Lai J.C., Wee R. Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year. Ophthalmologica. 2014;231(2):94–102. DOI: 10.1159/000354072
34. Oishi A., Kojima H., Mandai M., Honda S., Matsuoka T., Oh H., Kita M., Nagai T., Fujihara M., Bessho N., Uenishi M., Kurimoto Y., Negi A. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013 Oct;156(4):644–651. DOI: 10.1016/j. ajo.2013.05.024
35. Oishi A., Miyamoto N., Mandai M., Honda S., Matsuoka T., Oh H., Kita M., Nagai T., Bessho N., Uenishi M., Kurimoto Y., Negi A. LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology. 2014 May;121(5):1151–1152. DOI: 10.1016/j. ophtha.2013.12.037
36. Koh A., Lee W.K., Chen L.J., Chen S.J., Hashad Y., Kim H., Lai T.Y., Pilz S., Ruamviboonsuk P., Tokaji E., Weisberger A., Lim T.H. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453–1464.
37. Ogura Y., Terasaki H., Gomi F., Yuzawa M., Iida T., Honda M., Nishijo K., Sowade O., Komori T., Schmidt-Erfurth U., Simader C., Chong V. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015 Jan;99(1):92– 97. DOI: 10.1136/bjophthalmol-2014-305076
38. Yamamoto A., Okada A.A., Kano M., Koizumi H., Saito M., Maruko I., Sekiryu T., Iida T. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015 Sep;122(9):1866–1872. DOI: 10.1016/j. ophtha.2015.05.024
39. Oishi A., Tsujikawa A., Yamashiro K., Ooto S., Tamura H., Nakanishi H., UedaArakawa N., Miyake M., Akagi-Kurashige Y., Hata M., Yoshikawa M., Kuroda Y., Takahashi A., Yoshimura N. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015 May;159(5):853–860.e1. DOI: 10.1016/j.ajo.2015.01.018
40. Inoue M., Yamane S., Taoka R., Arakawa A., Kadonosono K. Aflibercept for polypoidal choroidal vasculopathy: as needed versus fixed interval dosing. Retina. 2016 Aug;36(8):1527–1534. DOI: 10.1097/IAE.0000000000000933
41. Arakawa A., Inoue M., Sato S., Yamane S., Kadonosono K. Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy. Clin Ophthalmol. 2017 Apr 27;11:797–802. DOI: 10.2147/OPTH.S129164
42. Wolff B., Vasseur V., Cahuzac A., Coscas F., Castelnovo L., Favard C., Michel G., Français C., Salomon L., Mauget-Faÿsse M. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population. Ophthalmologica. 2018;240(4):208–212. DOI: 10.1159/000488808
43. Gomi F., Sawa M., Wakabayashi T., Sasamoto Y., Suzuki M., Tsujikawa M. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010 Jul;150(1):48–54.e1. DOI: 10.1016/j.ajo.2010.02.008
44. Tomita K., Tsujikawa A., Yamashiro K., Ooto S., Tamura H., Otani A., Nakayama Y., Yoshimura N. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol. 2012 Jan;153(1):68–80.e1. DOI: 10.1016/j.ajo.2011.07.001
45. Sato T., Kishi S., Matsumoto H., Mukai R. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013 Jul;156(1):95–105.e1. DOI: 10.1016/j.ajo.2013.02.006
46. Mayorova A.M., Doga A.V., Pedanova E.K. Clinical and functional outcomes of combined treatment for polypoidal choroidal vasculopathy. Practical medicine = Prakticheskaya meditsina. 2018.3;(114):114–117 (In Russ.).
47. Koh A., Lai T.Y.Y., Takahashi K., Wong T.Y., Chen L.J., Ruamviboonsuk P., Tan C.S., Feller C., Margaron P., Lim T.H., Lee W.K. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017 Nov 1;135(11):1206–1213. DOI: 10.1001/jamaophthalmol.2017.4030
48. Lee W.K., Iida T., Ogura Y., Chen S.J., Wong T.Y., Mitchell P., Cheung G.C.M., Zhang Z., Leal S., Ishibashi T.; PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136(7):786–793. DOI: 10.1001/jamaophthalmol.2018.1804
49. Wong T.Y., Ogura Y., Lee W.K., Iida T., Chen S.-J., Mitchell P., Gemmy Cheung C.M., Zhang Z., Leal S., Ishibashi T., On Behalf Of The Planet Investigators, Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: 2-Year Results of the PLANET Study, American Journal of Ophthalmology. (2019), Publication stage: In Press Accepted Manuscript Published online: March 5, 2019. DOI: 10.1016/j.ajo.2019.02.027
Review
For citations:
Pedanova E.K., Doga A.V. Polypoidal Choroidal Vasculopathy Treatment: Photodynamic Therapy, Anti-VEGF Monotherapy or Combination. Review of Clinical Studies. Ophthalmology in Russia. 2019;16(2):151-158. (In Russ.) https://doi.org/10.18008/1816-5095-2019-2-151-158
Views:
2802
Email this article 